Spyre Therapeutics, Inc. (SYRE)
72.02
-0.98
(-1.34%)
USD |
NASDAQ |
May 07, 13:02
Spyre Therapeutics Cash from Investing (Quarterly) : 56.58M for March 31, 2026
Cash from Investing (Quarterly) Chart
Sep '18
Jan '19
May '19
285.00
270.00
255.00
240.00
Historical Data
Cash From Investing Definition
Cash from Investing is a major line item of the statement of cash flows. This metric tracks the movement of cash flows for the overall investing activities of the company. A few examples of investing activities include net change in PP&E, and net divestitures.
Cash from Investing (Quarterly) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Cash from Investing (Quarterly) Benchmarks
| Tyra Biosciences, Inc. | 34.38M |
| Replimune Group, Inc. | 75.12M |
| Savara, Inc. | -93.56M |
| Regeneron Pharmaceuticals, Inc. | -428.90M |
| Agios Pharmaceuticals, Inc. | 141.31M |
Cash from Investing (Quarterly) Related Metrics
| Cash from Operations (Quarterly) | -57.54M |
| Cash from Financing (Quarterly) | 12.43M |
| Free Cash Flow | -185.87M |
| Free Cash Flow Per Share (Quarterly) | -0.7326 |
| Free Cash Flow to Equity (Quarterly) | -57.54M |
| Free Cash Flow to Firm (Quarterly) | -57.54M |
| Free Cash Flow Yield | -3.75% |